About
Autolus is a clinical-stage, biopharmaceutical company, focused on the development and…
Activity
-
A heartfelt ‘Thank You’ from Our CEO, Adrian (Ad) Rawcliffe, as we celebrate our first FDA-approved therapy. 🌟 #Gratitude #Biotech #Innovation…
A heartfelt ‘Thank You’ from Our CEO, Adrian (Ad) Rawcliffe, as we celebrate our first FDA-approved therapy. 🌟 #Gratitude #Biotech #Innovation…
Liked by Chris Williams
-
Let's Talk Quality: The Podcast🎙️is back for Season Two this month! Here's a sneak peak from my conversation with Markus Gruell, SVP Quality at…
Let's Talk Quality: The Podcast🎙️is back for Season Two this month! Here's a sneak peak from my conversation with Markus Gruell, SVP Quality at…
Liked by Chris Williams
-
We have just entered into an exciting new deal with Flagship Pioneering that highlights our focus on harnessing the latest external advances in…
We have just entered into an exciting new deal with Flagship Pioneering that highlights our focus on harnessing the latest external advances in…
Liked by Chris Williams
Experience
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Education
-
Imperial College London
-
Christopher M J Williams, Angelo G Scibetta, J Karsten Friedrich, Monica Canosa, Chiara Berlato, Charlotte H Moss, Helen C Hurst. AP-2γ promotes proliferation in breast tumour cells by direct repression of the CDKN1A gene (2009). EMBO Journal Vol 28 Issue 22 pp3591.
-
-
More activity by Chris
-
We met the primary endpoint for our Ph2b study in PBC with setanaxib! A great milestone for Calliditas, but even greater to see the growing…
We met the primary endpoint for our Ph2b study in PBC with setanaxib! A great milestone for Calliditas, but even greater to see the growing…
Liked by Chris Williams
-
We are super excited to share the news of our successful €60 million ($65 million) Series B financing round, These funds will propel our metabolic…
We are super excited to share the news of our successful €60 million ($65 million) Series B financing round, These funds will propel our metabolic…
Liked by Chris Williams
-
As Mazzella Companies celebrates its 70th year in business, I'm reminded of growing up and hearing the stories of the early days and the trips I made…
As Mazzella Companies celebrates its 70th year in business, I'm reminded of growing up and hearing the stories of the early days and the trips I made…
Liked by Chris Williams
-
Delighted to announce the unveiling of our latest company creation with the (very oversubscribed) $165M Series A of Third Arc Bio. Opening credits:…
Delighted to announce the unveiling of our latest company creation with the (very oversubscribed) $165M Series A of Third Arc Bio. Opening credits:…
Liked by Chris Williams
-
Friday reflection - recapping 3 of the company launches we've completed so far this year ahead of a *new company announcement* next week: ❤️🔥…
Friday reflection - recapping 3 of the company launches we've completed so far this year ahead of a *new company announcement* next week: ❤️🔥…
Liked by Chris Williams
-
In the overhead lifting industry, I’m constantly reminded of the power of innovation and continuous learning. Every day, I’m lucky enough to witness…
In the overhead lifting industry, I’m constantly reminded of the power of innovation and continuous learning. Every day, I’m lucky enough to witness…
Liked by Chris Williams
-
Last week we were honored to have Robyn, Orca-T recipient and clinical trial participant, share her inspirational patient journey with our…
Last week we were honored to have Robyn, Orca-T recipient and clinical trial participant, share her inspirational patient journey with our…
Liked by Chris Williams
-
I am pleased to share that I have completed my Level 6 Laboratory Scientist Degree Apprenticeship and I have earned a BSc with honours in Applied…
I am pleased to share that I have completed my Level 6 Laboratory Scientist Degree Apprenticeship and I have earned a BSc with honours in Applied…
Liked by Chris Williams
-
This morning, we announced the appointment of Lucinda Crabtree, PhD as Chief Financial Officer and Board Member following Stuart Paynter’s decision…
This morning, we announced the appointment of Lucinda Crabtree, PhD as Chief Financial Officer and Board Member following Stuart Paynter’s decision…
Liked by Chris Williams
-
A fantastic networking evening hosted by Bobby Gaspar + Orchard Therapeutics - U.S. team and Noelia Sainz Pastor + the OUTbio UK team in Hammersmith…
A fantastic networking evening hosted by Bobby Gaspar + Orchard Therapeutics - U.S. team and Noelia Sainz Pastor + the OUTbio UK team in Hammersmith…
Liked by Chris Williams
-
Looking forward to joining forces with Biocytogen to generate novel ADCs for SOTIO's pipeline!
Looking forward to joining forces with Biocytogen to generate novel ADCs for SOTIO's pipeline!
Liked by Chris Williams
-
Today we say a fond farewell and thank you to Charlotte Casebourne Stock, Co-Founder and CEO, as she moves on to her next entrepreneurial endeavor…
Today we say a fond farewell and thank you to Charlotte Casebourne Stock, Co-Founder and CEO, as she moves on to her next entrepreneurial endeavor…
Liked by Chris Williams
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named Chris Williams in United Kingdom
-
Chris Williams
-
Chris Williams
-
Chris W.
-
Chris Williams
Associate Director - Supply Chain Recruitment at DSJ Global
-
Chris Williams
Managing Director at FEG Global | Delivering cross-sector CAPEX project management and environmental technology services
2126 others named Chris Williams in United Kingdom are on LinkedIn
See others named Chris Williams